The Biospecimen Core (Core B) provides part of the infrastructure support for Projects 1 - 4. This Core will provide a well-organized and standardized system of specimen collection, storage, distribution and related clinical/research information dissemination that is based on over two decades of experience. There will be consistency and quality assurance in the pathological analysis of tissue specimens. The Biospecimen Core is also involved in the maintenance of a large series of prostate cancer xenograft lines developed by Core investigators. These xenografts are used for proposed studies by the POI investigators and each study is overseen by Core personnel. Overall, the operations of this Core group into 4 components: 1. Specimen acquisition, processing, quality control, storage and accessioning into databases; 2. A prostate cancer xenograft maintenance, development and study program. 3. Laboratory services, including interpretation of tissues and tissue localization studies by a urologic pathologist, immunohistochemistry (IHC), quantitative RT-PCR, and immunoassays, i.e, PSA, and tissue culture. The Core will also perform pre-clinical studies using our xenograft resources;and 4. An administrative program to obtain samples from minority patients, prioritize the distribution of specimens, conduct a quality control program, and to ensure patient confidentiality and compliance with IRB requirements. The performance of each of the research projects detailed in this program project mandates that investigators have ready access to well documented clinical specimens and relevant biological models. The investigators directing the Biospecimen Core also make it a policy to provide excess prostate cancer specimen resources to POI collaborators and to non-P01 investigators on a world-wide basis. Overall, the Biospecimen Core is a critical component of this P01 program project.

Public Health Relevance

The Biospecimen Core is not hypothesis driven yet it is an essential component of this POI that enables the investigative teams to conduct hypothesis driven projects. Without adequate specimens and tumor models, both in quantity and quality, the science conducted by these investigators cannot be robust. The Biospecimen Core assures quality research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beth Israel Deaconess Medical Center
United States
Zip Code
Beshiri, Michael L; Tice, Caitlin M; Tran, Crystal et al. (2018) A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. Clin Cancer Res 24:4332-4345
Russo, Joshua W; Liu, Xiaming; Ye, Huihui et al. (2018) Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. Cancer Lett 438:97-104
Mostaghel, Elahe A (2018) Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer. Clin Cancer Res :
Uo, Takuma; Plymate, Stephen R; Sprenger, Cynthia C (2018) The potential of AR-V7 as a therapeutic target. Expert Opin Ther Targets 22:201-216
Arai, Seiji; Jonas, Oliver; Whitman, Matthew A et al. (2018) Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. Clin Cancer Res 24:5458-5470
Viswanathan, Srinivas R; Ha, Gavin; Hoff, Andreas M et al. (2018) Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell 174:433-447.e19
Russo, Joshua W; Gao, Ce; Bhasin, Swati S et al. (2018) Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res 78:6354-6362
Sowalsky, Adam G; Ye, Huihui; Bhasin, Manoj et al. (2018) Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res 78:4716-4730
Zhu, Yezi; Sharp, Adam; Anderson, Courtney M et al. (2018) Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. Eur Urol 73:727-735
Penning, Trevor M (2018) Dehydroepiandrosterone (DHEA)-SO4 Depot and Castration-Resistant Prostate Cancer. Vitam Horm 108:309-331

Showing the most recent 10 out of 90 publications